Mesoblast (MSB) Q3 2026 earnings summary

Executive summary

• Ryoncil® net revenues reached US$30.3M for the quarter, with gross sales of US$35.3M, driven by strong February and March sales.

• Net operating cash spend improved to US$4.1M, supported by US$34.6M in receipts and disciplined expense management.

• Patient recruitment target achieved in pivotal phase 3 trial for chronic low back pain.

• FDA cleared label extension trial for Ryoncil® in adults with SR-aGvHD and granted IND clearance for a registrational trial in Duchenne's muscular dystrophy.

• Acquired exclusive license to CAR technology platform for precision-enhanced cell therapy products.

Financial highlights

• Ryoncil® revenues for the first year since launch are approaching US$100M.

• Cash and cash equivalents at quarter end were US$121.8M.

• Payments to related parties totaled US$705K for the quarter.

• Estimated quarters of funding available is 41.8, based on current cash and financing facilities.

Outlook and guidance

• Commercial strategies are in place for continued revenue growth, with focus on label extensions and new indications.

• Near- and mid-term blockbuster opportunities identified in inflammatory back pain and heart failure.